The DIA 2018 Global Annual Meeting brings together thousands of innovators from around the globe.
Biosimilar Interchangeability: A Global Perspective
Executive Editor, US Policy and Regulatory
The Pink Sheet/Scrip, United States
Biosimilars are the next big thing in cost-saving – that's been the promise for a while now, but why aren't we there yet? This session will discuss the successes and stumbles so far and gain insight on stimulating market access for interchangeable biosimilars.
Learning Objective : Describe the various approaches regulators and payors in different countries have used to encourage the uptake of biosimilars; Compare the success of various education efforts for biosimilars; Identify how to plan strategies to address and take advantage of the specific market conditions for biosimilars in different countries; Analyze the incentives offered to sponsors to develop interchangeable biosimilars.
Steinar Madsen, MD
Norwegian Medicines Agency, Norway
Molly Burich, MPH
Director, Public Policy, Biosimilars and Reimbursements
Boehringer Ingelheim, United States
Chad Pettit, MBA
Executive Director, Biosimilars Global Value Access & Policy
Amgen Inc., United States